

Won Keun Chung*, Jin Hyun Chung and Kyoichi A. Watanabe*


College of Pharmacy, Seoul National University, Seoul, Korea and Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division of Graduate School of Medical Sciences, Cornell University, New York, NY 10021

Received August 6, 1982

A very simple method for the preparation of 5-fluorouracil (1) from 1,3-dimethyl-5-azauracil (2) by a novel ring transformation reaction is reported.

J. Heterocyclic Chem., **20**, 457 (1983).

5-Fluorouracil (1) one of the most extensively used drugs in the treatment of advanced solid cancers (2), has been prepared either *via* cyclization of α -formyl fluoroacetate with isothiourea (3) or by fluorination of uracil with fluoroxytrifluoromethane (4). Recent development of a novel *s*-triazine to pyrimidine ring transformation reaction in our laboratories (5) prompted us to extend the reaction for preparation of 1 from 1,3-dimethyl-5-azauracil (2). Treatment of 2 with fluoroacetamide (3) in alcoholic sodium alkoxide, the conditions employed for the *s*-triazine to pyrimidine transformation, did not afford 1. We found, however, that the transformation reaction occurred very smoothly in the presence of lithium diisopropylamide (LDA) and pure 1 was obtained in 88% yield from 2 and 3. This procedure may have wide applicability to the synthesis of a variety of fluorine substituted heterocyclic compounds.



EXPERIMENTAL

5-Fluorouracil (1).

A mixture of 2 (5.6) (1 g, 6 mmoles) and 3 (0.52 g, 6 mmoles) in 10% (w/w) LDA in ether (60 ml) was stirred at 0° for 4 hours under nitrogen. The precipitate was collected by filtration and recrystallized from methanol-ether to give 0.6 g (88%) of 1 mp 282-284° [lit (4), mp 282-283°]. The ¹H nmr and ir spectra of this sample were identical with those of an authentic sample.

REFERENCES AND NOTES

- (1) This investigation was supported in part by funds from the National Cancer Institute, D. H. H. S., Grants CA-08748 and CA-18601.
- (2) C. Heidelberger in "Antineoplastic and Immunosuppressive Agents", Part 2, A. C. Sartorelli and D. G. Johns, eds, Springer-Verlag, Heidelberg 1975, p 193.
- (3) R. Duschinsky, E. Plevin and C. Heidelberger, *J. Am. Chem. Soc.*, **79**, 4559 (1957).
- (4) D. H. H. Barton, R. H. Hesse, H. T. Toh and M. M. Pechet, *J. Org. Chem.*, **37**, 329 (1972).
- (5) W. K. Chung, C. K. Chu, K. A. Watanabe and J. J. Fox, *ibid.*, **44**, 3982 (1979).
- (6) A. Piskala and J. Gut, *Collect. Czech. Chem. Commun.*, **26**, 2516 (1961); *ibid.*, **28**, 1618 (1963).